Biodesix

Company Overview

Biodesix Inc. is involved in the development of an AI-based platform that provides diagnostic solutions focusing on genomics, transcriptomics, radiomics and proteomics. The company provides products and services for diagnosis (mainly lung disease), supportive information for the treatment, diagnostic research, CDx partnering and clinical research.

The company has developed the blood-based Nodify Lung nodule risk assessment testing (Nodify CDT test and Nodify XL2 test).

The company also provides the blood-based Lung Reflex testing service, GeneStrat tumor profiling test and VeriStrat immune profiling test for patients diagnosed with non-small cell lung cancer (NSCLC).

• The company is also developing the diagnostic assay for hepatocyte growth factor inhibitor antibody ficlatuzumab with AVEO Oncology (AVEO), using VeriStrat test as a CDx to identify NSCLC patients. The company is also expanding the potential of GeneStrat testing.

In January 2021, Biodesix Inc. and HiberCell entered into an agreement to develop enzyme-linked immunosorbent assay (ELISA) as a companion diagnostics test in future registrational trials in breast cancer for Imprime PGG programs.

Financial Highlights (FY 2024)

Company's Business Segments

• Lung Diagnostic : The company segments blood-based Nodify Lung and Nodule Risk Assessment testing, consisting of the Nodify XL2 and the Nodify CDT tests as lung diagnostic tests.
• Biopharma Services : The segment consists of various types of tests or scientific services for a purpose as defined by any customer.
• COVID-19 : The segment includes coronavirus diagnostic tests, including the Bio-Rad SARS-CoV-2 ddPCR test, the cPASS neutralization antibody test kit, and the Platelia SARS-CoV-2 tests.